Iris Wingrove
Neurology · Austin, TXNPI 1710008792
Payments from drug & device makers
Across 898 payments — averaging $18.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Teva Pharmaceuticals USA, Inc.$1K
- Pfizer$1K
- Lilly USA, LLC$948
- SK Life Science, Inc.$900
- Arbor Pharmaceuticals, Inc.$868
- plus $9K from 52 others
What the payments were for
- Consulting fees$1501%
- Food & beverage$16,19497%
- Education$3072%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,651 in reported general payments places this provider in the 70th percentile of 1,246 neurology providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GammakedImmune Globul G/Gly/Iga Avg 46 | 49 | $360,506 |
| PanzygaImmun Glob G(Igg)-Ifas/Glycine | 11 | $258,462 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 12 | $201,127 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 28 | $149,059 |
| NuplazidPimavanserin Tartrate | 20 | $99,698 |
| UbrelvyUbrogepant | 45 | $61,390 |
| NeuproRotigotine | 36 | $39,269 |
| NuedextaDextromethorphan Hbr/Quinidine | 14 | $36,632 |
| Nurtec OdtRimegepant Sulfate | 20 | $35,417 |
| XcopriCenobamate | 18 | $23,649 |
| Emgality PenGalcanezumab-Gnlm | 13 | $13,907 |
| Aimovig AutoinjectorErenumab-Aooe | 12 | $8,922 |
| NayzilamMidazolam | 13 | $8,921 |
| VyvanseLisdexamfetamine Dimesylate | 11 | $7,884 |
| Rivastigmine | 45 | $5,278 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Kedrion Biopharma, Inc.Gammaked | $25 | $360,50649 claims |
| PfizerPanzyga, Nurtec Odt | $1,129 | $293,87931 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid, Vyvanse | $279 | $209,01223 claims |
| CSL BehringPrivigen | $162 | $149,05928 claims |
| Acadia Pharmaceuticals IncNuplazid | $829 | $99,69820 claims |
| AbbVieUbrelvy | $1,933 | $61,39045 claims |
| UCB, Inc.Neupro, Nayzilam | $741 | $48,19049 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $114 | $36,63214 claims |
| SK Life Science, Inc.Xcopri | $900 | $23,64918 claims |
| Upsher-smith Laboratories LLCTopiramate | $390 | $16220 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,246 neurology providers in Texas.
Other neurology in Austin
- Esther MelamedAustin$593K
- Sami AboumatarAustin$593K
- Ann BassSan Antonio$12.3M
- Kandasami SenthilkumarBeaumont$7.6M
- Bharathy SundaramSherman$7.2M
- Bhupesh DiheniaLubbock$6.9M
- Jamshid LotfiHouston$6M
- Nazanin MajdHouston$5.9M
- Aziz ShaibaniHouston$5.5M
- Elizabeth PeckhamRound Rock$5.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.